Skip to content

Study · Animal study (in vivo) · rat · 2023

3 results

Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.

Shamardl HAMA, Ibrahim NA, Merzeban DH, Elamir AM, Golam RM, Elsayed AM

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences29 Mar 2023Cited by 22 (Europe PMC)

PMID36991247 (opens in a new tab)PMCIDPMC10238348 (opens in a new tab)DOI10.1007/s40199-023-00458-y (opens in a new tab)PepBankPUB-36991247
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundAdiposity and non-alcoholic fatty liver disease (NAFLD) are common characteristics of metabolic syndrome (MS). Understanding the underlying pathogenesis is crucial for the development of new remedies. Resveratrol controls obesity and glycemic disorders in patients with MS.ObjectivesThis study aimed to evaluate the effect of resveratrol and dulaglutide on adipose tissues and liver in rats with MS, declaring their possible mechanisms.MethodsRats allocated as Control, MS (induced by a high fat/ high sucrose diet for eight weeks), MS + Resveratrol (30 mg/kg/day orally), and MS + Dulaglutide (0.6 mg/kg twice weekly SC); drugs administration was in the last four weeks. Serum biochemical measurements were done. Liver and visceral fat were processed for biochemistry, histopathology, and immunohistochemistry.ResultsMS results demonstrated significantly increased systolic and diastolic blood pressure, anthropometric measurements, serum levels of alanine aminotransferase (ALT), glycemic indices, and lipids with decreased HDL-C. Tissue levels of leptin, malondialdehyde (MDA), and TNF-α reactivity significantly increased. Expression of adiponectin, PPARγ, and insulin growth factor-1 (IGF-1) decreased. Also, Western blotting mRNA gene expression of liver SIRT-1 was down-regulated. Resveratrol and dulaglutide significantly and effectively reversed MS complexity, ameliorating all findings, particularly NAFLD and adiposity-induced inflammation. Resveratrol significantly appears superior to dulaglutide regarding the effects on hemodynamics, lipids, adipokines, IGF-1 levels, and adipocyte size. Parallel, dulaglutide has more influence on glycemic control.ConclusionProtective effects of the drugs may be through correlations between SIRT-1/adipokines/IGF-1 and PPARγ, improving the cross-talk between insulin resistance, obesity markers, liver dysfunction, and TNF-α. Promising multi-beneficial therapies of resveratrol or dulaglutide in MS are recommended clinically for this purpose. Showing the Experimental Design.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with metabolic syndrome, dulaglutide ameliorated the reported abnormalities, particularly fatty liver and adiposity-induced inflammation.

    In plain wordsIn rats with metabolic syndrome, dulaglutide improved reported abnormalities compared with untreated metabolic syndrome.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedMetabolic syndrome abnormalities
    Study

    ratn: not reported in source

    Diet-induced metabolic syndrome
    Comparator
    Metabolic syndrome group
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    0.6 mg/kg twice weekly · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Resveratrol and dulaglutide significantly and effectively reversed MS complexity, ameliorating all findings, particularly NAFLD and adiposity-induced inflammation.
    1 context sentence
    Summary · context
    Rats allocated as Control, MS (induced by a high fat/ high sucrose diet for eight weeks), MS + Resveratrol (30 mg/kg/day orally), and MS + Dulaglutide (0.6 mg/kg twice weekly SC); drugs administration was in the last four weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with metabolic syndrome, dulaglutide had weaker effects than resveratrol on the listed hemodynamic, lipid, adipokine, IGF-1, and adipocyte outcomes.

    In plain wordsIn rats with metabolic syndrome, resveratrol had stronger effects than dulaglutide on these listed outcomes.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedHemodynamics, lipids, adipokines, IGF-1, and adipocyte size
    Study

    ratn: not reported in source

    Diet-induced metabolic syndrome
    Comparator
    Resveratrol
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    0.6 mg/kg twice weekly · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Resveratrol significantly appears superior to dulaglutide regarding the effects on hemodynamics, lipids, adipokines, IGF-1 levels, and adipocyte size.
    1 context sentence
    Summary · context
    Rats allocated as Control, MS (induced by a high fat/ high sucrose diet for eight weeks), MS + Resveratrol (30 mg/kg/day orally), and MS + Dulaglutide (0.6 mg/kg twice weekly SC); drugs administration was in the last four weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with metabolic syndrome, dulaglutide had more influence on glycemic control than resveratrol.

    In plain wordsIn rats with metabolic syndrome, dulaglutide affected glucose control more than resveratrol.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedGlycemic control
    Study

    ratn: not reported in source

    Diet-induced metabolic syndrome
    Comparator
    Resveratrol
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg/kg twice weekly · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Parallel, dulaglutide has more influence on glycemic control.
    2 context sentences
    Summary · context
    Resveratrol significantly appears superior to dulaglutide regarding the effects on hemodynamics, lipids, adipokines, IGF-1 levels, and adipocyte size.
    Summary · context
    Rats allocated as Control, MS (induced by a high fat/ high sucrose diet for eight weeks), MS + Resveratrol (30 mg/kg/day orally), and MS + Dulaglutide (0.6 mg/kg twice weekly SC); drugs administration was in the last four weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.